A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of neoantigens have no or low immunogenicity. Here, a bi-adjuvant neoantigen nanovaccine (banNV) that codelivered a peptide neoantigen (Adpgk) with two adjuvants [Toll-like receptor (TLR)...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Adv
Autori principali: Ni, Qianqian, Zhang, Fuwu, Liu, Yijing, Wang, Zhantong, Yu, Guocan, Liang, Brian, Niu, Gang, Su, Ting, Zhu, Guizhi, Lu, Guangming, Zhang, Longjiang, Chen, Xiaoyuan
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Association for the Advancement of Science 2020
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7080439/
https://ncbi.nlm.nih.gov/pubmed/32206706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aaw6071
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi